IPI-145 and ABT-199 for Lymphoid Malignancies

Publication
Article
Special ReportsHematologic Malignancies
Volume 1
Issue 1

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses IPI-145 and ABT-199 for the treatment of lymphoid malignancies.

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses IPI-145 and ABT-199 for the treatment of lymphoid malignancies.

Learn more about inhibiting BCL-2 > >

Articles in this issue
Comorbidities, Age, and Outcomes Among Intensively Treated Patients With AML
Comorbidities, Age, and Outcomes Among Intensively Treated Patients With AML
In the Pipeline: Potential New Treatments for AML
In the Pipeline: Potential New Treatments for AML
Epidemiology in B-Cell Malignancies
Epidemiology in B-Cell Malignancies
Pathogenesis of Follicular Lymphoma
Pathogenesis of Follicular Lymphoma
Resistance to Ibrutinib
Resistance to Ibrutinib
IPI-145 and ABT-199 for Lymphoid Malignancies
IPI-145 and ABT-199 for Lymphoid Malignancies
BCL-2 Inhibitor Combo May Offer Remissions in CLL
BCL-2 Inhibitor Combo May Offer Remissions in CLL
In Practice: Challenges in Treating Patients With Relapsed or Refractory CLL
In Practice: Challenges in Treating Patients With Relapsed or Refractory CLL
Recent Videos
Solly Chedid, MD, and Jamie Koprivnikar, MD
Solly Chedid, MD, and Jamie Koprivnikar, MD
Related Content
Ruxolitinib Stands Out Among JAK2 Inhibitors for Myelofibrosis

Ruxolitinib Stands Out Among JAK2 Inhibitors for Myelofibrosis

Targeted Oncology Staff
September 13th 2024
Article

Experts review the case of a 68-year-old woman diagnosed with primary myelofibrosis.

Read More

Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

Rohit Gosain, MD;Rahul Gosain, MD
April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen

In CLL/SLL, Zanubrutinib Linked to Lower Switch Rates vs Other BTK Inhibitors

In CLL/SLL, Zanubrutinib Linked to Lower Switch Rates vs Other BTK Inhibitors

Jax DiEugenio
September 12th 2024
Article

Findings from a real-world study showed that zanubrutinib was associated with lower rates of treatment switching and patients receiving subsequent therapy compared with acalabrutinib and ibrutinib in patients with CLL or SLL.

Read More

Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

Nichole Tucker;Cyrus M. Khan, MD
May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen

Superior Outcomes With Brentuximab Vedotin Triplet in Diffuse Large B-Cell Lymphoma

Superior Outcomes With Brentuximab Vedotin Triplet in Diffuse Large B-Cell Lymphoma

Kristi Rosa
September 11th 2024
Article

The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.

Read More

ADCs, Biomarker-Driven Therapies Will Be Prominent at Breast Cancer Conference

ADCs, Biomarker-Driven Therapies Will Be Prominent at Breast Cancer Conference

Tony Berberabe, MPH
September 11th 2024
Article

Breast cancer diagnostics, therapeutics, and biomarker-driven therapy will be important focal points during the 22nd Annual School of Breast Oncology conference.

Read More